Table 4 Multivariate Cox proportional hazards model to determine predictors of progression-free survival in patient treated with CDK4/6is pus ET.

From: Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies

Variables

MV-HR

95% CI

P value

Histology (compared to IDC)

 ILC

1.36

0.94–1.73

0.118

 Mixed

0.86

0.46–1.45

0.604

Race (compared to White)

 Black

0.91

0.65–1.24

0.583

 Hispanic

1.05

0.74–1.46

0.740

ET backbone (compared to AI)

 Fulvestrant

1.19

0.96–1.46

0.094

  1. CDK4/6is cyclin-dependent kinase 4 and 6 inhibitors, ET endocrine therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, Mixed mixed invasive ductal and lobular carcinoma, AI aromatase inhibitor, MV-HR multivariate hazard ratio, CI confidence interval.
Back to article page